Objective: To develop comprehensive recommendations for the treatment of the various
clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic …

Psoriasis is a frequent chronic inflammatory skin disease, nowadays considered a major
global health problem. Several new drugs, targeting the IL-23/IL-17A pathway, have been …

The ubiquitin-proteasome pathway has a central role in the selective degradation of intracellular
proteins. Among the key proteins modulated by the proteasome are those involved in …

Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting …

Objective To update the European League Against Rheumatism (EULAR) recommendations
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …

There is increasing awareness that psoriasis is more than ‘skin deep’. Several recent reviews
focussed on biomarkers indicating the systemic dimension of psoriasis and the aspect of …

Background The European Organisation for Research and Treatment of Cancer (EORTC)
1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected …

Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-…

Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence
of psoriasis in Western industrialized countries ranges from 1.5% to 2%. Patients afflicted …

Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated
inflammatory diseases. With five agents licensed, it was timely to summarise the …